ADXN
Addex Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ADXN
Addex Therapeutics Ltd
A company that developing allosteric modulators for human health care
Pharmaceutical
--
01/29/2020
NASDAQ Stock Exchange
2
12-31
Depository Receipts (Ordinary Shares)
Chemin des Mines 9, CH- 1202 Geneva, Switzerland
Committed to the development and commercialization of new oral newly discovered small molecule drugs
Addex Therapeutics Ltd is a Swiss limited liability company organised under the laws of Switzerland. The company was founded in 2002. The company is a clinical-stage pharmaceutical company dedicated to the development and commercialization of novel oral newly discovered small molecule drugs.
Earnings Call
Q4/2024
Estimate EPS--
Actual EPS--
Estimate Revenue181.05K
Actual Revenue--
Addex Therapeutics' Q4 2024: Navigating Contradictions in Dipraglurant Strategy and Muscarinic M4 Focus
May 02,2025 07:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ADXN has released its 2023 Q3 earnings. EPS was reported at -4.07, versus the expected 0, missing expectations. The chart below visualizes how ADXN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ADXN has released its 2025 Q2 earnings report, with revenue of 45.82K, reflecting a YoY change of -64.26%, and net profit of -2.32M, showing a YoY change of -116.19%. The Sankey diagram below clearly presents ADXN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
